1. Home
  2. Directory
  3. New Jersey
  4. Fair Lawn
  5. Podiatrist
  6. NPI Profile
  7. Prescriptions 1831116607

DR. WENDY GAYLE NACH D.P.M
Prescription History 1831116607
Podiatrist - Foot Surgery in Fair Lawn, NJ


Quality Rating: 75 out of 100 score

NPI Status: Active since July 16, 2006

Contact Information

15-01 BROADWAY
30C
FAIR LAWN, NJ
ZIP 07410
Phone: (201) 794-6656
Fax: (201) 794-7642

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. WENDY GAYLE NACH D.P.M, an active Foot Surgery specialist practicing in Fair Lawn, NJ. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 189 documented patient claims. Among these therapy options, the most frequently utilized medication is Meloxicam, which accounts for 38 claims alone.

Medication Index

C
G
J
M
N
No matching medications currently found on file.

Clotrimazole-Betamethasone

Generic Formulation: Clotrimazole/Betamethasone DipSpecialty: Podiatry
Provider Metrics Summary
Total Claims 30
30-Day Fills 32.0
Days Supply 721
NJ State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills29.1
Peer Average Days Supply652
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $607.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.24

State Avg Cost Per Claim

$34.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat a variety of inflamed fungal skin infections such as ringworm, athlete's foot, and jock itch. This product contains 2 medications. Clotrimazole is an azole antifungal that works by preventing the growth of fungus. Betamethasone is a strong corticosteroid that works by reducing the swelling, redness, and itching that occurs in the skin infection. This medication is not recommended for children younger than 17 years or for diaper rash.

Gabapentin

Generic Formulation: GabapentinSpecialty: Podiatry
Provider Metrics Summary
Total Claims 23
30-Day Fills 42.0
Days Supply 1,123
NJ State Average Benchmarks
Peer Average Claims73.0
Peer Average 30-Day Fills109.8
Peer Average Days Supply3,196
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.5% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $358.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.59

State Avg Cost Per Claim

$19.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Jublia

Generic Formulation: EfinaconazoleSpecialty: Podiatry
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 750
NJ State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills24.0
Peer Average Days Supply712
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 38.9% more claims than the standard regional baseline profile for NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $23,055.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$922.22

State Avg Cost Per Claim

$1,549.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat toenail infection caused by fungus. It works by stopping the growth of certain types of fungus. Efinaconazole belongs to a class of drugs known as azole antifungals. This medication treats only fungal infections. It will not work for other types of infection, such as those caused by bacteria. Unnecessary use or overuse of any drug used to treat infection can lead to its decreased effectiveness.

Meloxicam

Generic Formulation: MeloxicamSpecialty: Podiatry
Provider Metrics Summary
Total Claims 38
30-Day Fills 42.0
Days Supply 1,260
NJ State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills67.9
Peer Average Days Supply1,965
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $120.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.18

State Avg Cost Per Claim

$5.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.

Therapeutic Applications

Meloxicam is used to help relieve moderate to severe pain. Meloxicam is known as a nonsteroidal anti-inflammatory drug (NSAID). It works by blocking your body's production of certain natural substances that cause inflammation. This effect helps to decrease swelling or pain.

Mupirocin

Generic Formulation: MupirocinSpecialty: Podiatry
Provider Metrics Summary
Total Claims 30
30-Day Fills 30.3
Days Supply 527
NJ State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills38.7
Peer Average Days Supply622
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $314.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.49

State Avg Cost Per Claim

$11.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.

Therapeutic Applications

Mupirocin is used to treat certain skin infections (such as impetigo). It is an antibiotic. It works by stopping the growth of certain bacteria.

Nystatin

Generic Formulation: NystatinSpecialty: Podiatry
Provider Metrics Summary
Total Claims 23
30-Day Fills 25.0
Days Supply 620
NJ State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills26.9
Peer Average Days Supply456
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $577.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.09

State Avg Cost Per Claim

$26.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.

Therapeutic Applications

Nystatin is used to treat fungal skin infections. Nystatin is an antifungal that works by stopping the growth of fungus.

Nystop

Generic Formulation: NystatinSpecialty: Podiatry
Provider Metrics Summary
Total Claims 20
30-Day Fills 22.0
Days Supply 549
NJ State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills19.4
Peer Average Days Supply388
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $455.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.77

State Avg Cost Per Claim

$39.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.

Therapeutic Applications

Nystatin is used to treat fungal skin infections. Nystatin is an antifungal that works by stopping the growth of fungus.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. WENDY GAYLE NACH D.P.M provides transparency into local medical care patterns within Fair Lawn, NJ.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Foot Surgery** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.